Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nan Cheng

Showing results (501-510 of 557) with videos related to

Pageof 56
Sort By:
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Theranostics|March 23, 2021
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphomaQingzhu Jia, Diyuan Qin, Feng He, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 12, 2018
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutionsMing-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 28, 2022
The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter studyGuangjie Yang, Pei Nie, Lei Yan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2022
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsVincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, et al.
The Journal of Infectious Diseases|April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Pageof 56

Showing results (501-510 of 557) with videos related to

Sort By:
Pageof 56
Journal of Hepatology|October 5, 2024
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infectionChen-Hua Liu, Pin-Nan Cheng, Yu-Jen Fang, et al.
Theranostics|March 23, 2021
Peripheral eosinophil counts predict efficacy of anti-CD19 CAR-T cell therapy against B-lineage non-Hodgkin lymphomaQingzhu Jia, Diyuan Qin, Feng He, et al.
Journal of Gastroenterology and Hepatology|April 2, 2019
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysisChen-Hua Liu, Yu-Lueng Shih, Sheng-Shun Yang, et al.
Hepatology Communications|May 16, 2018
Elbasvir/grazoprevir in Asia-Pacific/Russian participants with chronic hepatitis C virus genotype 1, 4, or 6 infectionJacob George, Eduard Burnevich, I-Shyan Sheen, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 12, 2018
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutionsMing-Lung Yu, Chao-Hung Hung, Yi-Hsiang Huang, et al.
Journal of Gastroenterology|April 13, 2024
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antiviralsChen-Hua Liu, Yu-Ping Chang, Yu-Jen Fang, et al.
European Journal of Nuclear Medicine and Molecular Imaging|March 28, 2022
The radiomics-based tumor heterogeneity adds incremental value to the existing prognostic models for predicting outcome in localized clear cell renal cell carcinoma: a multicenter studyGuangjie Yang, Pei Nie, Lei Yan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|January 25, 2022
Performance of Noninvasive Tests of Fibrosis Among Asians, Hispanic, and non-Hispanic Whites in the STELLAR TrialsVincent Wai-Sun Wong, Won Young Tak, George Boon Bee Goh, et al.
The Journal of Infectious Diseases|April 9, 2019
An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated SubstitutionsChung-Feng Huang, Chao-Hung Hung, Pin-Nan Cheng, et al.
Nature Medicine|June 21, 2022
Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a studyStephen A Harrison, Federico Perez Manghi, William B Smith, et al.
Pageof 56